CombinatoRx shares surge on diabetes data

Shares of CombinatoRx surged 39 percent this morning on the news that its experimental diabetes drug hit its primary endpoint in a mid-stage trial. The combination of bezafibrate and diflunisal produced better data than bezafibrate alone. CRx-401 is described as an insulin sensitizer intended to provide a better therapy to patients without weight gain. Report

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.